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vations over a long period, and outcome in people with type 2
diabetes treated with insulin. METHODS: Data were extracted
from GPRD. An index of glucose variability was generated using
RBG observations over a sustained period (10 years from
insulin initiation) in subjects with 5 RBG observations using
the difference between the maximum and minimum RBG obser-
vation (DMax-MinRBG). Cox proportional hazards models were
developed characterising time to ﬁrst events for: acute myocar-
dial infarction (AMI), stroke, and severe visual loss, as well as for
all-cause mortality. Recognised vascular disease risk factors were
accounted for. RESULTS: There were 4238 subjects who met the
inclusion criteria. The subjects excluded were found to be more
poorly than those included, with shorter follow up and a greater
likelihood of having ever smoked. There was an association
between DMax-MinRBG and HbA1c whereby subjects with good
control were more like to have low variability. Following stan-
dardisation for potentially confounding factors, DMax-MinRBG
(m.mol/l) was associated with all-cause mortality (hazard
ratio [HR] = 1.026 per m.mol/l glucose; p = 0.020); stroke
(HR = 1.046; p < 0.001), and severe visual loss/blindness
(HR = 1.040; p = 0.025). For these three endpoints, DMax-MinRBG
was a better predictor of outcome than was HbA1c, whereas in
AMI, DMax-Min RBG was not signiﬁcant, and HbA1c was
(poor control versus good control: HR = 1.53; p = 0.034). CON-
CLUSION: Although we were unsure why general practitioners
were recording RBG observations, glucose variability over a
sustained period, as measured by DMax-MinRBG, was strongly
associated with all-cause mortality, stroke and vision loss in
people with type 2 diabetes treated with insulin, and more so
than was mean HbA1c over the same extended period.
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OBJECTIVES: Basal insulin administered to type 2 diabetes
patients with poor glycemic control, when managed with oral
therapy alone, can lead to an increased risk of weight gain and
hypoglycemia. A meta-analysis of randomized controlled trials
(RCTs) using treat-to-target protocols was conducted to indi-
rectly compare insulin detemir with insulin glargine on the fol-
lowing outcomes: weight gain, hypoglycemic episodes, and
HbA1c. METHODS: Parallel-group RCTs of at least 20 weeks
duration that compared once-daily glargine or detemir with a
common comparator, NPH insulin (bedtime), in insulin-naïve,
poorly controlled type 2 diabetes patients receiving oral therapy,
were selected. Five open-label trials were identiﬁed (N = 2551
patients; N = 1 detemir and N = 4 glargine trials). A ﬁxed-effects
meta-analysis was used, with an indirect comparison of glargine
(N = 2047 patients) and detemir trials (N = 504 patients) carried
out using meta-regression. Weight gain and mean HbA1c change
from baseline were analyzed as weighted mean differences
(WMD). Mean Hba1c level at study endpoint was analyzed as
standardized mean differences (SMD), and total hypoglycemic
episodes per study were analyzed as odds-ratios (OR). Further
analyses were conducted which adjusted for covariates. Dosing
formulas were comparable across studies. RESULTS: Patients
receiving evening detemir gained signiﬁcantly less weight (unad-
justed WMD -1.22, 95% CI -2.15, -0.29; p = 0.010) and had a
signiﬁcantly lower total number of hypoglycemic episodes versus
evening glargine (unadjusted OR 0.52, 95% CI 0.28, 0.98;
p = 0.044). Mean change from baseline in HbA1c level favored
evening glargine, but there was no signiﬁcant difference between
treatments for mean HbA1c level at study endpoint (unadjusted
SMD 0.09, 95% CI -0.16, 0.33; p = 0.480). CONCLUSION:
Detemir appears similar to glargine in terms of achieving glyce-
mic control, but is superior to the latter for controlling weight
gain and reducing the incidence of hypoglycemic episodes in this
population.
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OBJECTIVES: In the UK, the role of insulin initiation has tradi-
tionally been one for specialist (secondary care) diabetes teams
(SDT) but this trend is changing. The increasing role of primary
care (PC) in diabetes management highlights the need for appro-
priate resource planning. This analysis describes the initial ﬁnd-
ings of a UK primary care audit of patients who were newly
initiated on insulin. METHODS: Data were collected from 8
primary care practices in the UK, covering a total of 58,452
people. Medical records were reviewed to ascertain the preva-
lence of type 2 diabetes mellitus (T2DM), those who initiated
insulin in the last 3 years and associated patient and treatment
details. RESULTS: A total of 2005 patients (3.4%) had a diag-
nosis of T2DM. Insulin was initiated in 316 patients with a mean
age at initiation of 63 years and duration of illness of 8 years. Of
these 149 had been initiated in the last three years (62% PC,
28% SDT) leading to an estimate of annual insulin initiations of
2.19% of all people with type 2 diabetes. The mean HbA1c
closest to insulin initiation was similar for PC (10.6%) and SDT
(10.4%) patients and 54% patients had BMI  30 kg/m2.
Patients commonly initiate insulin following two or more oral
medications (57%), the most common being metformin plus a
sulphonylurea. Pre-mixed insulins and long acting insulin ana-
logues were common, although use differed between PC (59%
long acting insulin analogues) and SDT (49% pre-mixed insulin).
CONCLUSION: In the UK, around 2% of people with T2DM
will be initiated on insulin annually. The majority of these are
initiated within a primary care setting and with HbA1c levels
which are above international clinical targets. Given the trend to
manage more diabetes in primary care, appropriate resources
need to be available to support patients through this intensiﬁca-
tion of therapy.
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OBJECTIVES: To conﬁrm or refute a possible association
between intense Topical Corticosteroid (TC) use and new-onset
diabetes and establish whether it increases with dose and dura-
tion of TC use. METHODS: Data for this nested case-control
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